SEARCH:   Advanced

Blood, 2 April 2009, Vol. 113, No. 14, pp. 3307-3313. Prepublished online as a Blood First Edition Paper on September 3, 2008; DOI 10.1182/blood-2008-03-148874. This Article Full Text Full Text (PDF) Supplemental Appendix All Versions of this Article: blood-2008-03-148874v1 113/14/3307    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ribrag, V. Articles by Salles, G. Search for Related Content PubMed PubMed Citation Articles by Ribrag, V. Articles by Salles, G. Related Collections Lymphoid Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  LYMPHOID NEOPLASIA Pharmacogenetic study in Hodgkin lymphomas reveals the impact of UGT1A1 polymorphisms on patient prognosis Vincent Ribrag1, Serge Koscielny2, Olivier Casasnovas3, Cecile Cazeneuve4, Pauline Brice5, Franck Morschhauser6, Jean Gabarre7, Aspasia Stamatoullas8, Gilbert Lenoir4, Gilles Salles9, on Behalf from the Groupe d'Etude des Lymphomes agressifs group, Laboratoire de Génétique et de recherche translationnelle, and Institut Gustave Roussy 1 Laboratoire de recherche translationnelle, Institut Gustave Roussy (IGR), Villejuif; 2 Département de statistiques, IGR, Villejuif; 3 Hopital Le Bocage, Dijon; 4 Laboratoire de génétique, IGR, Villejuif; 5 Hopital Saint Louis, Paris; 6 Centre Hospitalier Universitaire de Lille, Lille; 7 Hopital Pitié-Salpétrière, Paris; 8 Centre Henri Becquerel, Rouen; and 9 Hospices Civils de Lyon, Université de Lyon, UMR 5139 du Centre National de la Recherche Scientifique, Lyon, France Hodgkin lymphoma is a highly curable malignancy, but treatment outcome might be influenced by inherited gene polymorphisms determining anticancer agent metabolism. We prospectively collected peripheral blood lymphocytes from 313 patients with Hodgkin lymphomas to analyze GSTP1, GSTM1, GSTT1, UGT1A1, and CYP3A4 enzyme gene polymorphisms. All patients were treated with chemotherapy, associated with radiotherapy when they had localized disease. There was no difference for GSTP1, GSTM1, and GSTT1 as well as for UGT1A1 and CYP3A4 polymorphism distributions between Hodgkin lymphoma patients and healthy controls. Patients carrying 1 or 2 UGT1A1*28 allele had a significantly (P < .05) better freedom from progression and time to treatment failure than those homozygous for the UGT1A1 TA6/TA6 allele. Multivariate prognostic analyses showed that the UGT1A1 polymorphism was as an independent prognostic parameter for all the studied endpoints, the wild-type homozygous UGT1A1 TA6/TA6 genotype being associated with a significantly worse prognosis than genotypes with at least one UGT1A1*28 allele (overall survival; relative risk [RR] = 2.54, 95% confidence interval [CI], 1.05-6.14; P = .04; freedom from progression, RR = 2.70, 95% CI, 1.37-5.31; P = .004; time to treatment failure, RR = 2.37, 95% CI, 1.28-4.40, P = .006). UGT1A1 polymorphism on TA repeats, which are thought to determine several anticancer drugs metabolism, influence Hodgkin lymphoma patient outcome. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

	Copyright © 2009 by American Society of Hematology         Online ISSN: 1528-0020